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Interleukin-1R antagonist (anakinra) induces disease
remission in about 50% of corticosteroid (CS) resistant
cases of systemic onset JIA (SOJIA) [1,2]. Clinicians
debate whether etanercept should still be tried first before
giving anakinra to such patients. Another, more chaleng-
ing, issue is to start anakinra even in CS naïve SOJIA
patients. We here report our first experiences of such an
approach in 7 patients with SOJIA. Four patients had
recent onset SOJIA (3 weeks to 3 months) with classical
spiking fever, exanthema and arthritis, 3 had a recent flare.
They were all treated with indomethacin for at least 2
weeks without effect. There were no signs of haemophago-
cytosis. Anakinra was started (2 mg/kg sc daily) as an in-
patient procedure to monitor for disease progression. Dis-
ease activity was monitored at 0, 24, 72 hr and 3 weeks.
Fever and exanthema disappeared within 24 hours, arthri-
tis within 3 days. One child had a recurrence of arthritis
without fever or exanthema after 2 weeks. The mean val-
ues at t = 72 hrs: CRP decreased from 178 to 33, ESR from
120 to 94, ferritin from 1260 to 375. In 3 of 5 tested NK
cell function restored within 72 hr.
Current follow up of 3 weeks anakinra showed persistent
remission in 6/7 without the use of CS.
Based on these short term results we would like to pro-
pose a RCT (PRINTO?) to define the place of anakinra
with a read-out of disease activity and prednisone use.
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